Abstract

BackgroundReplication-deficient recombinant adenoviral vectors based on human serotype 35 (Ad35) are desirable due to the relatively low prevalence of neutralizing antibodies in the human population. The structure of the viral genome and life cycle of Ad35 differs from the better characterized Ad5 and these differences require differences in the strategies for the generation of vectors for gene delivery.ResultsSequences essential for E1 and E4 function were identified and removed and the effects of the deletions on viral gene transcription were determined. In addition, the non-essential E3 region was deleted from rAd35 vectors and a sequence was found that did not have an effect on viability but reduced viral fitness. The packaging capacity of rAd35 was dependent on pIX and vectors were generated with stable genome sizes of up to 104% of the wild type genome size. These data were used to make an E1-, E3-, E4-deleted rAd35 vector. This rAd35 vector with multiple gene deletions has the advantages of multiple blocks to viral replication (i.e., E1 and E4 deletions) and a transgene packaging capacity of 7.6 Kb, comparable to rAd5 vectors.ConclusionsThe results reported here allow the generation of larger capacity rAd35 vectors and will guide the derivation of adenovirus vectors from other serotypes.

Highlights

  • Recombinant adenovirus-based gene transfer vectors are currently under investigation in a variety of gene therapy and vaccine clinical trials

  • There are more than 370 such clinical trials that are ongoing for broad applications, including infectious diseases and cancer therapy http://www.wiley.com//legacy/wileychi/genmed/ clinical/. Many of these trials are of recombinant adenovirus vectors based on the human serotype 5 (Ad5) yet there are advantages to Recombinant adenovirus (rAd) vectors derived from other serotypes

  • adenoviral vectors based on human serotype 35 (Ad35) capsid components and identification of the early/ late switch To facilitate the derivation of rAd35 vectors with multiple genome deletions the protein components of wild type virions were determined

Read more

Summary

Introduction

Recombinant adenovirus (rAd)-based gene transfer vectors are currently under investigation in a variety of gene therapy and vaccine clinical trials. There are more than 370 such clinical trials that are ongoing for broad applications, including infectious diseases and cancer therapy http://www.wiley.com//legacy/wileychi/genmed/ clinical/. Many of these trials are of recombinant adenovirus (rAd) vectors based on the human serotype 5 (Ad5) yet there are advantages to rAd vectors derived from other serotypes. Exposure of human populations to adenovirus serotype 35 (Ad35) has been shown to be relatively rare based on the prevalence of Ad35 neutralizing antibodies in sera [1,2,3,4,5]. Replication-deficient recombinant adenoviral vectors based on human serotype 35 (Ad35) are desirable due to the relatively low prevalence of neutralizing antibodies in the human population. The structure of the viral genome and life cycle of Ad35 differs from the better characterized Ad5 and these differences require differences in the strategies for the generation of vectors for gene delivery

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call